4-Cyan-3-isopropylpyridin | 20970-82-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-Cyan-3-isopropylpyridin
• 英文别名: 3-isopropyl-isonicotinonitrile；3-Isopropylisonicotinonitrile；3-propan-2-ylpyridine-4-carbonitrile
• CAS: 20970-82-5
• 化学式: C₉H₁₀N₂
• 分子量: 146.192
• InChiKey: BXLMQBMNIDNHOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS
  申请人：Samumed, LLC

  公开号：US20140243349A1

  公开（公告）日：2014-08-28

  The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

  本公开提供了激活Wnt/β-连环蛋白信号通路并因此治疗或预防与信号转导相关的疾病的γ-二酮或其类似物；这些疾病包括骨质疏松症和骨关节病；骨发育不全、骨缺陷、骨折、牙周病、耳硬化症、伤口愈合、颅颌面缺陷、溶骨性骨病、创伤性脑损伤或脊柱损伤、与中枢神经系统分化和发育相关的脑萎缩/神经系统疾病，包括帕金森病、中风、缺血性脑疾病、癫痫、阿尔茨海默病、抑郁症、躁郁症、精神分裂症；耳部疾病如耳蜗毛细胞丧失；眼部疾病如老年性黄斑变性、糖尿病性黄斑水肿或视网膜色素变性以及与干细胞分化和生长相关的疾病，如脱发、造血相关疾病和组织再生相关疾病。
• SUBSTITUTED VINYL AND ALKINYL CYCLOHEXENOLS AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS
  申请人：Frackenpohl Jens

  公开号：US20140080704A1

  公开（公告）日：2014-03-20

  The invention relates to substituted vinyl- and alkynylcyclohexenols of the general formula (I) and salts thereof where the R 1 , R 2 , R 3 , R 4 , R 5 , [X—Y] and Q radicals are each as defined in the description, to processes for preparation thereof and to the use thereof for enhancing stress tolerance in plants with respect to abiotic stress, and/or for increasing plant yield.

  该发明涉及通式（I）中的取代乙烯基和炔基环己烯醇及其盐，其中R1、R2、R3、R4、R5、[X—Y]和Q基团如描述中所定义，以及其制备方法和用途，用于增强植物对非生物胁迫的抗逆性，和/或增加植物产量。
• [EN] CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER<br/>[FR] COMPOSÉS DE CINNOLINE POUR LE TRAITEMENT DE TROUBLES DÉPENDANT DU HPK1 TELS QUE LE CANCER
  申请人：GENENTECH INC

  公开号：WO2020069402A1

  公开（公告）日：2020-04-02

  Cinnoline compounds of formula (I), variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.

  该文描述了化学式(I)的喹啉化合物及其变体，以及它们作为HPK1（造血激酶1）抑制剂的用途。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面具有用途。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备喹啉化合物的方法。
• SUBSTITUTED VINYL AND ALKYNYL CYANOCYCLOALKANOLS AND VINYL AND ALKYNYL CYANOHETEROCYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS
  申请人：BAYER CROPSCIENCE AKTIENGESELLSCHAFT

  公开号：US20170197910A1

  公开（公告）日：2017-07-13

  Substituted vinyl- and alkynylcyanocycloalkanols and vinyl- and alkynylcyanoheterocyclylalkanols of the general formula (I) or salts thereof where [X—Y], Q, R 1 , R 2 , A 1 , A 2 , V, W, m and n are each as defined in the description, processes for preparation thereof and the use thereof for enhancing stress tolerance in plants with respect to abiotic stress, and/or for increasing plant yield.

  通式（I）的取代乙烯基和炔基氰基环戊醇和乙烯基和炔基氰基杂环烷基醇或其盐，其中[X—Y]，Q，R1，R2，A1，A2，V，W，m和n均如描述中定义的那样，其制备方法以及用于增强植物对非生物胁迫的耐受性和/或增加植物产量的用途。
• BENZOTHIAZOL COMPOUNDS AND METHODS USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS
  申请人：1ST Biotherapeutics, Inc.

  公开号：US20190100500A1

  公开（公告）日：2019-04-04

  The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound.

  本公开提供了具有c-abl激酶抑制活性或其药用盐的一般式（I）化合物，包括该化合物的药物组合物，以及使用该化合物治疗或预防神经退行性疾病的方法。